Impact of COVID-19 on venture-backed biotech companies – Part 2: Investment and cash flow
by Adrian Toutoungi and Josef Fuss
Impact of COVID-19 on venture-backed biotech companies – Part 1: Operational issues
by Adrian Toutoungi and Josef Fuss
NHS can procure drugs for use outside of their approved indications if it's cheaper, court says
Everything biologic and biosimilar in-house counsel need to know about COVID-19
by multiple authors
Patent pools: an easy licensing option for COVID-19 drugs and SARS CoV 2 vaccines?
An exploration of patent pools, R&D and current initiatives.
by Dr. Anja Lunze, LL.M. and Dr. Jan Phillip Rektorschek
2 of 6 Insights
Termination, force majeure and frustration – international perspectives on the life sciences sector
by multiple authors
COVID-19 and life sciences M&A
by multiple authors
Marketing authorisation and clinical testing of new drugs
Competition law issues shaping the pharmaceutical sector
by Paolo Palmigiano and Louisa Penny
Special approvals of the Federal Institute for Drugs and Medical Devices for the distribution of medical devices and FFP breathing masks without an expiration valve